Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q2 EPS of $0.18, $0.27 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $12 million versus the consensus estimate of $6.5 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.